Emerging science of the human microbiome

Gut Microbes

Volumn 5, Issue 4, 2014, Pages 446-457

  Jones, Mitchell L ^b   Ganopolsky, Jorge G ^b   Martoni, Christopher J ^b   Labbé, Alain ^b   Prakash, Satya ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b Micropharma Limited   (Canada)

Author keywords

Antibiotics; Diet; Dysbiosis; Immune system; Metabolic disease; Microbiome; Prebiotics; Probiotics

Indexed keywords

DEXTRIN; FARNESOID X RECEPTOR; FRUCTOSE OLIGOSACCHARIDE; G PROTEIN COUPLED RECEPTOR; GALACTOSE OLIGOSACCHARIDE; GLUCAGON LIKE PEPTIDE 1; GUAR GUM; GUM ARABIC; IMMUNOGLOBULIN A; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INULIN; ISPAGULA; LIPOPOLYSACCHARIDE; POLYPEPTIDE ANTIBIOTIC AGENT; PREBIOTIC AGENT; PROBIOTIC AGENT; SHORT CHAIN FATTY ACID; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; VITAMIN B GROUP; VITAMIN K GROUP;

ANTIBIOTIC ASSOCIATED DIARRHEA; ARTICLE; AUTOIMMUNE DISEASE; BACTEROIDES FRAGILIS; BACTEROIDES THETAIOTAOMICRON; BIFIDOBACTERIUM; BILE ACID METABOLISM; BODY MASS; CLOSTRIDIUM PERFRINGENS; DIABETES MELLITUS; DYSBIOSIS; FAECALIBACTERIUM; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOMODULATION; INFLAMMATORY BOWEL DISEASE; IRRITABLE COLON; LACTOBACILLUS RHAMNOSUS; LYMPHOCYTE ACTIVATION; METHANOBREVIBACTER SMITHI; MICROBIAL COMMUNITY; MICROBIAL DEGRADATION; MICROBIAL GENOME; MICROBIOME; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PREVOTELLA; SACCHAROMYCES BOULARDII; COMMUNICABLE DISEASE; HEALTH; METAGENOMICS; MICROBIOLOGY; MICROFLORA; TRENDS;

COMMUNICABLE DISEASES; HEALTH; HOST-PATHOGEN INTERACTIONS; HUMANS; METAGENOMICS; MICROBIOLOGY; MICROBIOTA;

EID: 84907845387     PISSN: 19490976     EISSN: 19490984     Source Type: Journal    
DOI: 10.4161/gmic.29810     Document Type: Article

References (140)

1. Bianconi E, Piovesan A, Facchin F, Beraudi A, Casadei R, Frabetti F, Vitale L, Pelleri MC, Tassani S, Piva F, et al. An estimation of the number of cells in the human body. Ann Hum Biol 2013; 40:463-71; PMID:23829164; http://dx.doi.org/10.3109/03014460.2013.807878
2. Whitman WB, Coleman DC, Wiebe WJ. Prokaryotes: the unseen majority. Proc Natl Acad Sci U S A 1998; 95:6578-83; PMID:9618454; http://dx.doi.org/10.1073/pnas.95.12.6578
3. Bäckhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI. Host-bacterial mutualism in the human intestine. Science 2005; 307:1915-20; PMID:1579 08 4 4; http://dx.doi.org/10.1126/science.1104816
4. Ley RE, Peterson DA, Gordon JI. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell 2006; 124:837-48; PMID:16497592; http://dx.doi.org/10.1016/j.cell.2006.02.017
5. Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JI. The human microbiome project. Nature 2007; 449:804-10; PMID:17943116; http://dx.doi.org/10.1038/nature06244
6. Lederberg J. ‘Ome Sweet ‘Omics–A Genealogical Treasury of Words. The Scientist 2001:15
7. Staley JT, Konopka A. Measurement of in situ activities of nonphotosynthetic microorganisms in aquatic and terrestrial habitats. Annu Rev Microbiol 1985; 39:321-46; PMID:3904603; http://dx.doi.org/10.114 6/annurev.mi.39.100185.001541
8. Tringe SG, Hugenholtz P. A renaissance for the pioneering 16S rRNA gene. Curr Opin Microbiol 2008; 11:442-6; PMID:18817891; http://dx.doi.org/10.1016/j.mib.2008.09.011
9. O’Hara AM, Shanahan F. The gut flora as a forgotten organ. EMBO Rep 2006; 7:688-93; PM I D:16 819 4 6 3; http://dx.doi.org/10.1038/sj.embor.7400731
10. Flint HJ, Bayer EA, Rincon MT, Lamed R, White BA. Polysaccharide utilization by gut bacteria: potential for new insights from genomic analysis. Nat Rev Microbiol 2008; 6:121-31; PMID:18180751; http://dx.doi.org/10.1038/nrmicro1817
11. Sonnenburg JL, Xu J, Leip DD, Chen CH, Westover BP, Weatherford J, Buhler JD, Gordon JI. Glycan foraging in vivo by an intestine-adapted bacterial sym-biont. Science 2005; 307:1955-9; PMID:15790854; http://dx.doi.org/10.1126/science.1109051
12. LeBlanc JG, Milani C, de Giori GS, Sesma F, van Sinderen D, Ventura M. Bacteria as vitamin suppliers to their host: a gut microbiota perspective. Curr Opin Biotechnol 2013; 24:160-8; PMID:22940212; http://dx.doi.org/10.1016/j.copbio.2012.08.005
13. Resta SC. Effects of probiotics and commensals on intestinal epithelial physiology: implications for nutrient handling. J Physiol 2009; 587:4169-74; PMID:19596893; http://dx.doi.org/10.1113/jphysiol.2009.176370
14. Goodman AL, McNulty NP, Zhao Y, Leip D, Mitra RD, Lozupone CA, Knight R, Gordon JI. Identifying genetic determinants needed to establish a human gut symbiont in its habitat. Cell Host Microbe 2009; 6:279-89; PMID:19748469; http://dx.doi.org/10.1016/j.chom.2009.08.003
15. Beg AA. ComPPARtmentalizing NF-kappaB in the gut. Nat Immunol 2004; 5:14-6; PMID:14699401; http://dx.doi.org/10.1038/ni0104-14
16. Littman DR, Pamer EG. Role of the commensal microbiota in normal and pathogenic host immune responses. Cell Host Microbe 2011; 10:311-23; PMID:22018232; http://dx.doi.org/10.1016/j.chom.2011.10.004
17. Ventura M, Turroni F, Motherway MO, MacSharry J, van Sinderen D. Host-microbe interactions that facilitate gut colonization by commensal bifi-dobacteria. Trends Microbiol 2012; 20:467-76; PMID:22902802; http://dx.doi.org/10.1016/j.tim.2012.07.002
18. Hardy H, Harris J, Lyon E, Beal J, Foey AD. Probiotics, prebiotics and immunomodulation of gut mucosal defences: homeostasis and immunopathol-ogy. Nutrients 2013; 5:1869-912; PMID:23760057; http://dx.doi.org/10.3390/nu5061869
19. Mitsuoka T, Hidaka H, Eida T. Effect of fructo-oligosaccharides on intestinal microflora. Nahrung 1987; 31:427-36; PMID:3657917; http://dx.doi.org/10.1002/food.19870310528
20. Xu J, Bjursell MK, Himrod J, Deng S, Carmichael LK, Chiang HC, Hooper LV, Gordon JI. A genomic view of the human-Bacteroides thetaio-taomicron symbiosis. Science 2003; 299:2074-6; PMID:12663928; http://dx.doi.org/10.1126/science.1080029
21. Lee SM, Donaldson GP, Mikulski Z, Boyajian S, Ley K, Mazmanian SK. Bacterial colonization factors control specificity and stability of the gut micro-biota. Nature 2013; 501:426-9; PMID: 23955152; http://dx.doi.org/10.1038/nature12447
22. Freeland KR, Wilson C, Wolever TM. Adaptation of colonic fermentation and glucagon-like peptide-1 secretion with increased wheat fibre intake for 1 year in hyperinsulinaemic human subjects. Br J Nutr 2010; 103:82-90; PMID:19664300; http://dx.doi.org/10.1017/S0007114509991462
23. Wichmann A, Allahyar A, Greiner TU, Plovier H, Lundén GO, Larsson T, Drucker DJ, Delzenne NM, Cani PD, Bäckhed F. Microbial modulation of energy availability in the colon regulates intestinal transit. Cell Host Microbe 2013; 14:582-90; PMID:24237703; http://dx.doi.org/10.1016/j.chom.2013.09.012
24. Brestoff JR, Artis D. Commensal bacteria at the interface of host metabolism and the immune system. Nat Immunol 2013; 14:676-84; PMID:23778795; http://dx.doi.org/10.1038/ni.2640
25. Cox MA, Jackson J, Stanton M, Rojas-Triana A, Bober L, Laverty M, Yang X, Zhu F, Liu J, Wang S, et al. Short-chain fatty acids act as antiinflammatory mediators by regulating prostaglandin E(2) and cytokines. World J Gastroenterol 2009; 15:5549-57; PMID:19938193; http://dx.doi.org/10.3748/wjg.15.5549
26. Le Poul E, Loison C, Struyf S, Springael JY, Lannoy V, Decobecq ME, Brezillon S, Dupriez V, Vassart G, Van Damme J, et al. Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J Biol Chem 2003; 278:25481-9; PMID:12711604; http://dx.doi.org/10.1074/jbc.M301403200
27. Patel KK, Stappenbeck TS. Autophagy and intestinal homeostasis. Annu Rev Physiol 2013; 75:241-62; PMID:23216414; http://dx.doi.org/10.1146/annurev-physiol-030212-183658
28. Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly Y M, Glickman JN, Garrett WS. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 2013; 341:569-73; PMID:23828891; http://dx.doi.org/10.1126/science.1241165
29. Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 2009; 89:147-91; PMID:19126757; http://dx.doi.org/10.1152/physrev.00010.2008
30. Begley M, Gahan CGM, Hill C. The interaction between bacteria and bile. FEMS Microbiol Rev 2005; 29: 625-51; PMID:16102595; http://dx.doi.org/10.1016/j.femsre.2004.09.003
31. de Aguiar Vallim TQ, Tarling EJ, Edwards PA. Pleiotropic roles of bile acids in metabolism. Cell Metab 2013; 17:657-69; PMID:23602448; http://dx.doi.org/10.1016/j.cmet.2013.03.013
32. Swann JR, Want EJ, Geier FM, Spagou K, Wilson ID, Sidaway JE, Nicholson JK, Holmes E. Systemic gut microbial modulation of bile acid metabolism in host tissue compartments. Proc Natl Acad Sci U S A 2011; 108(Suppl 1):4523-30; PMID:20837534; http://dx.doi.org/10.10 73/pnas.1006734107
33. Watanabe M, Houten SM, Wang L, Moschetta A, Mangelsdorf DJ, Heyman RA, Moore DD, Auwerx J. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 2004; 113:1408-18; PMID: 15146238; http://dx.doi.org/10.1172/JCI21025
34. Zhang Y, Lee FY, Barrera G, Lee H, Vales C, Gonzalez FJ, Willson TM, Edwards PA. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A 2006; 103:1006-11; PMID:16410358; http://dx.doi.org/10.1073/pnas.0506982103
35. Schaap FG. Role of fibroblast growth factor 19 in the control of glucose homeostasis. Curr Opin Clin Nutr Metab Care 2012; 15:386-91; PMID: 22617565; http://dx.doi.org/10.1097/MCO.0b013e3283547171
36. Matsubara T, Li F, Gonzalez FJ. FXR signaling in the enterohepatic system. Mol Cell Endocrinol 2013; 368:17-29; PMID:22609541; http://dx.doi.org/10.1016/j.mce.2012.05.004
37. Wang YD, Chen WD, Yu D, Forman BM, Huang W. The G-protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor κ light-chain enhancer of activated B cells (NF-κB) in mice. Hepatology 2011; 54:1421-32; PMID:21735468; http://dx.doi.org/10.1002/hep.24525
38. Maruyama T, Tanaka K, Suzuki J, Miyoshi H, Harada N, Nakamura T, Miyamoto Y, Kanatani A, Tamai Y. Targeted disruption of G protein-coupled bile acid receptor 1 (Gpbar1/M-Bar) in mice. J Endocrinol 2006; 191:197-205; PMID:17065403; http://dx.doi.org/10.1677/joe.1.06546
39. Sato H, Genet C, Strehle A, Thomas C, Lobstein A, Wagner A, Mioskowski C, Auwerx J, Saladin R. Anti-hyperglycemic activity of a TGR5 agonist isolated from Olea europaea. Biochem Biophys Res Commun 2007; 362:793-8; PMID:17825251; http://dx.doi.org/10.1016/j.bbrc.2007.06.130
40. Katsuma S, Hirasawa A, Tsujimoto G. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem Biophys Res Commun 2005; 329:386-90; PMID:15721318; http://dx.doi.org/10.1016/j.bbrc.2005.01.139
41. Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G, Macchiarulo A, Yamamoto H, Mataki C, Pruzanski M, et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 2009; 10:167-77; PMID:19723493; http://dx.doi.org/10.1016/j.cmet.2009.08.001
42. Lavoie B, Balemba OB, Godfrey C, Watson CA, Vassileva G, Corvera CU, Nelson MT, Mawe GM. Hydrophobic bile salts inhibit gallbladder smooth muscle function via stimulation of GPBAR1 receptors and activation of KATP channels. J Physiol 2010; 588:3295-305; PMID:20624794; http://dx.doi.org/10.1113/jphysiol.2010.192146
43. Li T, Holmstrom SR, Kir S, Umetani M, Schmidt DR, Kliewer SA, Mangelsdorf DJ. The G protein-coupled bile acid receptor, TGR5, stimulates gallbladder filling. Mol Endocrinol 2011; 25:1066-71; PMID:21454404; http://dx.doi.org/10.1210/me.2010-0460
44. Vassileva G, Golovko A, Markowitz L, Abbondanzo SJ, Zeng M, Yang S, Hoos L, Tetzloff G, Levitan D, Murgolo NJ, et al. Targeted deletion of Gpbar1 protects mice from cholesterol gallstone formation. Biochem J 2006; 398:423-30; PMID:16724960; http://dx.doi.org/10.1042/BJ20060537
45. Clemente JC, Ursell LK, Parfrey LW, Knight R. The impact of the gut microbiota on human health: an integrative view. Cell 2012; 148:1258-70; PMID:22424233; http://dx.doi.org/10.1016/j.cell.2012.01.035
46. Dethlefsen L, Huse S, Sogin ML, Relman DA. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol 2008; 6:e280; PMID:19018661; http://dx.doi.org/10.1371/journal.pbio.0060280
47. Kashyap PC, Marcobal A, Ursell LK, Smits SA, Sonnenburg ED, Costello EK, Higginbottom SK, Domino SE, Holmes SP, Relman DA, et al. Genetically dictated change in host mucus carbohydrate landscape exerts a diet-dependent effect on the gut microbiota. Proc Natl Acad Sci U S A 2013; 110:17059-64; PMID:24062455; http://dx.doi.org/10.1073/pnas.1306070110
48. Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, Fernandes GR, Tap J, Bruls T, Batto JM, et al.; MetaHIT Consortium. Enterotypes of the human gut microbiome. Nature 2011; 473:174-80; PMID: 215 0 8 9 5 8; http://dx.doi.org/10.1038/nature09944
49. Faith JJ, Guruge JL, Charbonneau M, Subramanian S, Seedorf H, Goodman AL, Clemente JC, Knight R, Heath AC, Leibel RL, et al. The long-term stability of the human gut microbiota. Science 2013; 341:1237439; PMID:23828941; http://dx.doi.org/10.1126/science.1237439
50. Costello EK, Lauber CL, Hamady M, Fierer N, Gordon JI, Knight R. Bacterial community variation in human body habitats across space and time. Science 2009; 326:1694-7; PMID:1989294 4; http://dx.doi.org/10.1126/science.1177486
51. Vanhoutte T, Huys G, Brandt E, Swings J. Temporal stability analysis of the microbiota in human feces by denaturing gradient gel electrophoresis using universal and group-specific 16S rRNA gene primers. FEMS Microbiol Ecol 2004; 48:437-46; PMID:19712312; http://dx.doi.org/10.1016/j.femsec.2004.03.001
52. Koenig JE, Spor A, Scalfone N, Fricker AD, Stombaugh J, Knight R, Angenent LT, Ley RE. Succession of microbial consortia in the developing infant gut microbiome. Proc Natl Acad Sci U S A 2011; 108(Suppl 1):4578-85; PMID:20668239; http://dx.doi.org/10.1073/pnas.1000081107
53. Gosalbes MJ, Llop S, Vallès Y, Moya A, Ballester F, Francino MP. Meconium microbiota types dominated by lactic acid or enteric bacteria are differentially associated with maternal eczema and respiratory problems in infants. Clin Exp Allergy 2013; 43:198-211; PMID:23331561; http://dx.doi.org/10.1111/cea.12063
54. Moles L, Gómez M, Heilig H, Bustos G, Fuentes S, de Vos W, Fernández L, Rodríguez JM, Jiménez E. Bacterial diversity in meconium of preterm neo-nates and evolution of their fecal microbiota during the first month of life. PLoS One 2013; 8:e66986; PMID:23840569; http://dx.doi.org/10.1371/journal.pone.0066986
55. Hu J, Nomura Y, Bashir A, Fernandez-Hernandez H, Itzkowitz S, Pei Z, Stone J, Loudon H, Peter I. Diversified microbiota of meconium is affected by maternal diabetes status. PLoS One 2013; 8:e78257; PMID:2422314 4; http://dx.doi.org/10.1371/journal.pone.0078257
56. Dominguez-Bello MG, Costello EK, Contreras M, Magris M, Hidalgo G, Fierer N, Knight R. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in new-borns. Proc Natl Acad Sci U S A 2010; 107:11971-5; PMID:20566857; http://dx.doi.org/10.1073/pnas.1002601107
57. Huurre A, Kalliomäki M, Rautava S, Rinne M, Salminen S, Isolauri E. Mode of delivery - effects on gut microbiota and humoral immunity. Neonatology 2008; 93:236-40; PMID:18025796; http://dx.doi.org/10.1159/000111102
58. Palmer C, Bik EM, DiGiulio DB, Relman DA, Brown PO. Development of the human infant intestinal microbiota. PLoS Biol 2007; 5:e177; PMID: 1759 4176; http://dx.doi.org/10.1371/journal.pbio.0050177
59. Claesson MJ, Cusack S, O’Sullivan O, Greene-Diniz R, de Weerd H, Flannery E, Marchesi JR, Falush D, Dinan T, Fitzgerald G, et al. Composition, variability, and temporal stability of the intestinal microbiota of the elderly. Proc Natl Acad Sci U S A 2011; 108(Suppl 1): 4586-91; PMID: 2 057 1116; http://dx.doi.org/10.1073/pnas.1000097107
60. Lee SM, Donaldson GP, Mikulski Z, Boyajian S, Ley K, Mazmanian SK. Bacterial colonization factors control specificity and stability of the gut microbiota. Nature 2013; 501: 426-9; PMID: 2 3 9 55152; http://dx.doi.org/10.1038/nature12447
61. Ikehara Y, Nishihara S, Yasutomi H, Kitamura T, Matsuo K, Shimizu N, Inada K, Kodera Y, Yamamura Y, Narimatsu H, et al. Polymorphisms of two fucos-yltransferase genes (Lewis and Secretor genes) involving type I Lewis antigens are associated with the presence of anti-Helicobacter pylori IgG antibody. Cancer Epidemiol Biomarkers Prev 2001; 10:971-7; PMID:11535550
62. Lindesmith L, Moe C, Marionneau S, Ruvoen N, Jiang X, Lindblad L, Stewart P, LePendu J, Baric R. Human susceptibility and resistance to Norwalk virus infection. Nat Med 2003; 9:548-53; PMID:12692541; http://dx.doi.org/10.1038/nm860
63. Ruiz-Palacios GM, Cervantes LE, Ramos P, Chavez-Munguia B, Newburg DS. Campylobacter jejuni binds intestinal H(O) antigen (Fuc alpha 1, 2Gal beta 1, 4GlcNAc), and fucosyloligosaccharides of human milk inhibit its binding and infection. J Biol Chem 2003; 278:14112-20; PMID:12562767; http://dx.doi.org/10.1074/jbc.M207744200
64. Hildebrand F, Nguyen TL, Brinkman B, Yunta RG, Cauwe B, Vandenabeele P, Liston A, Raes J. Inflammation-associated enterotypes, host genotype, cage and inter-individual effects drive gut micro-biota variation in common laboratory mice. Genome Biol 2013; 14:R4; PMID:23347395; http://dx.doi.org/10.1186/gb-2013-14-1-r4
65. Turnbaugh PJ, Quince C, Faith JJ, McHardy AC, Yatsunenko T, Niazi F, Affourtit J, Egholm M, Henrissat B, Knight R, et al. Organismal, genetic, and transcriptional variation in the deeply sequenced gut microbiomes of identical twins. Proc Natl Acad Sci U S A 2010; 107:7503-8; PMID:20363958; http://dx.doi.org/10.1073/pnas.1002355107
66. Ridaura VK, Faith JJ, Rey FE, Cheng J, Duncan AE, Kau AL, Griffin NW, Lombard V, Henrissat B, Bain JR, et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science 2013; 341:1241214; PMID:24009397; http://dx.doi.org/10.1126/science.1241214
67. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature 2006; 444:1022-3; PMID:17183309; http://dx.doi.org/10.1038/4441022a
68. Faith JJ, McNulty NP, Rey FE, Gordon JI. Predicting a human gut microbiota’s response to diet in gnotobi-otic mice. Science 2011; 333:101-4; PMID: 2 15 9 6 9 5 4; http://dx.doi.org/10.1126/science.1206025
69. Mahowald MA, Rey FE, Seedorf H, Turnbaugh PJ, Fulton RS, Wollam A, Shah N, Wang C, Magrini V, Wilson RK, et al. Characterizing a model human gut microbiota composed of members of its two dominant bacterial phyla. Proc Natl Acad Sci U S A 2009; 106:5859-64; PM I D:19 321416; http://dx.doi.org/10.1073/pnas.0901529106
70. Samuel BS, Gordon JI. A humanized gnotobiotic mouse model of host-archaeal-bacterial mutualism. Proc Natl Acad Sci U S A 2006; 103:10011-6; PMID:16782812; http://dx.doi.org/10.1073/pnas.0602187103
71. David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, Ling AV, Devlin AS, Varma Y, Fischbach MA, et al. Diet rapidly and repro-ducibly alters the human gut microbiome. Nature 2014; 505:559-63; PMID:24336217; http://dx.doi.org/10.1038/nature12820
72. Gibson GR, Beatty ER, Wang X, Cummings JH. Selective stimulation of bifidobacteria in the human colon by oligofructose and inulin. Gastroenterology 1995; 108:975-82; PMID:7698613; http://dx.doi.org/10.1016/0016-5085(95)90192-2
73. Calame W, Weseler AR, Viebke C, Flynn C, Siemensma AD. Gum arabic establishes prebiotic functionality in healthy human volunteers in a dose-dependent manner. Br J Nutr 2008; 100:1269-75; PMID:18466655; http://dx.doi.org/10.1017/S0007114508981447
74. Costabile A, Kolida S, Klinder A, Gietl E, Bäuerlein M, Frohberg C, Landschütze V, Gibson GR. A double-blind, placebo-controlled, cross-over study to establish the bifidogenic effect of a very-long-chain inulin extracted from globe artichoke (Cynara scoly-mus) in healthy human subjects. Br J Nutr 2010; 104:1007-17; PMID:20591206; http://dx.doi.org/10.1017/S0007114510001571
75. Elli M, Cattivelli D, Soldi S, Bonatti M, Morelli L. Evaluation of prebiotic potential of refined psyl-lium (Plantago ovata) fiber in healthy women. J Clin Gastroenterol 2008; 42(Suppl 3 Pt 2):S174-6; PMID:18685505; http://dx.doi.org/10.1097/MCG.0b013e31817f183a
76. ®, a soluble fibre with prebiotic properties, may be beneficial for health. J Int Med Res 2012; 40:211-24; PMID: 22429361; http://dx.doi.org/10.1177/147323001204000122
77. Ramnani P, Gaudier E, Bingham M, van Bruggen P, Tuohy KM, Gibson GR. Prebiotic effect of fruit and vegetable shots containing Jerusalem artichoke inulin: a human intervention study. Br J Nutr 2010; 104:233-40; PMID:20187995; http://dx.doi.org/10.1017/S000711451000036X
78. Whelan K. Mechanisms and effectiveness of prebiot-ics in modifying the gastrointestinal microbiota for the management of digestive disorders. Proc Nutr Soc 2013; 72:288-98; PMID:23680358; http://dx.doi.org/10.1017/S0029665113001262
79. Wu GD, Chen J, Hoffmann C, Bittinger K, Chen Y Y, Keilbaugh SA, Bewtra M, Knights D, Walters WA, Knight R, et al. Linking long-term dietary patterns with gut microbial enterotypes. Science 2011; 33 4:105-8; PMID:21885731; http://dx.doi.org/10.1126/science.1208344
80. Pérez-Cobas AE, Gosalbes MJ, Friedrichs A, Knecht H, Artacho A, Eismann K, Otto W, Rojo D, Bargiela R, von Bergen M, et al. Gut microbiota disturbance during antibiotic therapy: a multi-omic approach. Gut 2013; 62:1591-601; PMID:23236009; http://dx.doi.org/10.1136/gutjnl-2012-303184
81. Hu Y, Yang X, Qin J, Lu N, Cheng G, Wu N, Pan Y, Li J, Zhu L, Wang X, et al. Metagenome-wide analysis of antibiotic resistance genes in a large cohort of human gut microbiota. Nat Commun 2013; 4: 2151; PMID: 23877117; http://dx.doi.org/10.1038/ncomms3151
82. Ng KM, Ferreyra JA, Higginbottom SK, Lynch JB, Kashyap PC, Gopinath S, Naidu N, Choudhury B, Weimer BC, Monack DM, et al. Microbiota-liberated host sugars facilitate post-antibiotic expansion of enteric pathogens. Nature 2013; 502:96-9; PMID:23995682; http://dx.doi.org/10.1038/nature12503
83. Weiner HL, da Cunha AP, Quintana F, Wu H. Oral tolerance. Immunol Rev 2011; 241:241-59; PMID:21488901; http://dx.doi.org/10.1111/j.1600-065X.2011.01017.x
84. Blaser MJ, Falkow S. What are the consequences of the disappearing human microbiota? Nat Rev Microbiol 2009; 7:887-94; PMID:19898491; http://dx.doi.org/10.1038/nrmicro2245
85. Vijay-Kumar M, Aitken JD, Carvalho FA, Cullender TC, Mwangi S, Srinivasan S, Sitaraman SV, Knight R, Ley RE, Gewirtz AT. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 2010; 328:228-31; PMID:20203013; http://dx.doi.org/10.1126/science.1179721
86. Frazão JB, Errante PR, Condino-Neto A. Toll-like receptors’ pathway disturbances are associated with increased susceptibility to infections in humans. Arch Immunol Ther Exp (Warsz) 2013; 61:427-43; PMID:24057516; http://dx.doi.org/10.1007/s00005-013-0243-0
87. Belkaid Y, Naik S. Compartmentalized and systemic control of tissue immunity by commensals. Nat Immunol 2013; 14:646-53; PMID:23778791; http://dx.doi.org/10.1038/ni.2604
88. Brown EM, Sadarangani M, Finlay BB. The role of the immune system in governing host-microbe interactions in the intestine. Nat Immunol 2013; 14:660-7; PMID:23778793; http://dx.doi.org/10.1038/ni.2611
89. Chu H, Mazmanian SK. Innate immune recognition of the microbiota promotes host-microbial symbiosis. Nat Immunol 2013; 14:668-75; PMID:23778794; http://dx.doi.org/10.1038/ni.2635
90. Kamada N, Chen GY, Inohara N, Núñez G. Control of pathogens and pathobionts by the gut microbiota. Nat Immunol 2013; 14:685-90; PMID:23778796; http://dx.doi.org/10.1038/ni.2608
91. Weinstock GM. Genomic approaches to studying the human microbiota. Nature 2012; 489:250-6; PMID:22972298; http://dx.doi.org/10.1038/nature11553
92. Brown K, DeCoffe D, Molcan E, Gibson DL. Diet-induced dysbiosis of the intestinal microbiota and the effects on immunity and disease. Nutrients 2012; 4:1095-119; PMID: 23016134; http://dx.doi.org/10.3390/nu4081095
93. Karlsson FH, Fåk F, Nookaew I, Tremaroli V, Fagerberg B, Petranovic D, Bäckhed F, Nielsen J. Symptomatic atherosclerosis is associated with an altered gut metagenome. Nat Commun 2012; 3:1245; PMID:23212374; http://dx.doi.org/10.1038/ncomms2266
94. Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, Liang S, Zhang W, Guan Y, Shen D, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 2012; 490:55-60; PMID:23023125; http://dx.doi.org/10.1038/nature11450
95. Larsen N, Vogensen FK, van den Berg F W, Nielsen DS, Andreasen AS, Pedersen BK, Al-Soud WA, Sørensen SJ, Hansen LH, Jakobsen M. Gut micro-biota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One 2010; 5:e9085; PMID:20140211; http://dx.doi.org/10.1371/journal.pone.0009085
96. Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, Almeida M, Arumugam M, Batto JM, Kennedy S, et al.; MetaHIT consortium. Richness of human gut microbiome correlates with metabolic markers. Nature 2013; 500:541-6; PMID:23985870; http://dx.doi.org/10.1038/nature12506
97. Jones BV, Begley M, Hill C, Gahan CG, Marchesi JR. Functional and comparative metagenomic analysis of bile salt hydrolase activity in the human gut micro-biome. Proc Natl Acad Sci U S A 2008; 105:13580-5; PMID:18757757; http://dx.doi.org/10.1073/pnas.0804437105
98. Machiels K, Joossens M, Sabino J, De Preter V, Arijs I, Eeckhaut V, Ballet V, Claes K, Van Immerseel F, Verbeke K, et al. A decrease of the butyrate-produc-ing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut 2014; 63:1275-83; PMID:24021287; http://dx.doi.org/10.1136/gutjnl-2013-304833
99. Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 2002; 347:911-20; PMID:12239261; http://dx.doi.org/10.1056/NEJMra020100
100. Cotillard A, Kennedy SP, Kong LC, Prifti E, Pons N, Le Chatelier E, Almeida M, Quinquis B, Levenez F, Galleron N, et al.; ANR MicroObes consortium. Dietary intervention impact on gut microbial gene richness. Nature 2013; 500:585-8; PMID:23985875; http://dx.doi.org/10.1038/nature12480
101. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, et al.; MetaHIT Consortium. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010; 464:59-65; PMID:20203603; http://dx.doi.org/10.1038/nature08821
102. Lepage P, Häsler R, Spehlmann ME, Rehman A, Zvirbliene A, Begun A, Ott S, Kupcinskas L, Doré J, Raedler A, et al. Twin study indicates loss of interaction between microbiota and mucosa of patients with ulcerative colitis. Gastroenterology 2011; 141:227-36; PMID:21621540; http://dx.doi.org/10.1053/j.gastro.2011.04.011
103. Manichanh C, Rigottier-Gois L, Bonnaud E, Gloux K, Pelletier E, Frangeul L, Nalin R, Jarrin C, Chardon P, Marteau P, et al. Reduced diversity of faecal micro-biota in Crohn’s disease revealed by a metagenomic approach. Gut 2006; 55:205-11; PMID:16188921; http://dx.doi.org/10.1136/gut.2005.073817
104. Cho I, Yamanishi S, Cox L, Methé BA, Zavadil J, Li K, Gao Z, Mahana D, Raju K, Teitler I, et al. Antibiotics in early life alter the murine colonic microbiome and adiposity. Nature 2012; 488:621-6; PMID:22914093; http://dx.doi.org/10.1038/nature11400
105. Behnsen J, Deriu E, Sassone-Corsi M, Raffatellu M. Probiotics: properties, examples, and specific applications. Cold Spring Harb Perspect Med 2013; 3:a010074; PMID:23457295; http://dx.doi.org/10.1101/cshperspect.a010074
106. Sanders ME, Guarner F, Guerrant R, Holt PR, Quigley EM, Sartor RB, Sherman PM, Mayer EA. An update on the use and investigation of probiot-ics in health and disease. Gut 2013; 62:787-96; PMID:23474 420; http://dx.doi.org/10.1136/gutjnl-2012-302504
107. Whelan K, Quigley EM. Probiotics in the management of irritable bowel syndrome and inflammatory bowel disease. Curr Opin Gastroenterol 2013; 29:184-9; PMID:23286925; http://dx.doi.org/10.1097/MOG.0b013e32835d7bba
108. Bäckhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, Semenkovich CF, Gordon JI. The gut micro-biota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A 2004; 101:15718-23; PMID: 15 5 0 5215; http://dx.doi.org/10.1073/pnas.0407076101
109. Duboc H, Rajca S, Rainteau D, Benarous D, Maubert MA, Quervain E, Thomas G, Barbu V, Humbert L, Despras G, et al. Connecting dysbio-sis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut 2013; 62:531-9; PMID:22993202; http://dx.doi.org/10.1136/gutjnl-2012-302578
110. Duboc H, Rainteau D, Rajca S, Humbert L, Farabos D, Maubert M, Grondin V, Jouet P, Bouhassira D, Seksik P, et al. Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil 2012; 24:513-20, e246-7; PMID:22356587; http://dx.doi.org/10.1111/j.1365-2982.2012.01893.x
111. Ogilvie LA, Jones BV. Dysbiosis modulates capacity for bile acid modification in the gut microbiomes of patients with inflammatory bowel disease: a mechanism and marker of disease? Gut 2012; 61:1642-3; PMID:22490526; http://dx.doi.org/10.1136/gutjnl-2012-302137
112. Welters CF, Heineman E, Thunnissen FB, van den Bogaard AE, Soeters PB, Baeten CG. Effect of dietary inulin supplementation on inflammation of pouch mucosa in patients with an ileal pouch-anal anastomosis. Dis Colon Rectum 2002; 45:621-7; PMID:12004211; http://dx.doi.org/10.1007/s10350-004-6257-2
113. Wong JM, Kendall CW, de Souza R, Emam A, Marchie A, Vidgen E, Holmes C, Jenkins DJ. The effect on the blood lipid profile of soy foods combined with a prebiotic: a randomized controlled trial. Metabolism 2010; 59:1331-40; PMID:20096897; http://dx.doi.org/10.1016/j.metabol.2009.12.017
114. Drakoularakou A, Tzortzis G, Rastall RA, Gibson GR. A double-blind, placebo-controlled, randomized human study assessing the capacity of a novel galacto-oligosaccharide mixture in reducing travellers’ diarrhoea. Eur J Clin Nutr 2010; 64:146-52; PMID: 19756029; http://dx.doi.org/10.1038/ejcn.2009.120
115. Silk DB, Davis A, Vulevic J, Tzortzis G, Gibson GR. Clinical trial: the effects of a trans-galactooligosac-charide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment Pharmacol Ther 2009; 29:508-18; PMID:19053980; http://dx.doi.org/10.1111/j.1365-2036.2008.03911.x
116. Parisi GC, Zilli M, Miani MP, Carrara M, Bottona E, Verdianelli G, Battaglia G, Desideri S, Faedo A, Marzolino C, et al. High-fiber diet supplemen tation in patients with irritable bowel syndrome (IBS): a multicenter, randomized, open trial com parison between wheat bran diet and partially hydrolyzed guar gum (PHGG). Dig Dis Sci 2002; 47:1697-704; PMID:12184518; http://dx.doi.org/10.1023/A:1016419906546
117. Hsiao EY, McBride SW, Hsien S, Sharon G, Hyde ER, McCue T, Codelli JA, Chow J, Reisman SE, Petrosino JF, et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell 2013; 155:1451-63; PMID: 24315484; http://dx.doi.org/10.1016/j.cell.2013.11.024
118. Scher JU, Sczesnak A, Longman RS, Segata N, Ubeda C, Bielski C, Rostron T, Cerundolo V, Pamer EG, Abramson SB, et al. Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. Elife 2013; 2:e01202; PMID: 24192039; http://dx.doi.org/10.7554/eLife.01202
119. Mouzaki M, Comelli EM, Arendt BM, Bonengel J, Fung SK, Fischer SE, McGilvray ID, Allard JP. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology 2013; 58:120-7; PMID:23401313; http://dx.doi.org/10.1002/hep.26319
120. Raman M, Ahmed I, Gillevet PM, Probert CS, Ratcliffe NM, Smith S, Greenwood R, Sikaroodi M, Lam V, Crotty P, et al. Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2013; 11:868-75, e1-3; PMID:23454028; http://dx.doi.org/10.1016/j.cgh.2013.02.015
121. Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O’Mahony L, Kiely B, Shanahan F, Quigley EM. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006; 101: 1581-90; PMID:16863564; http://dx.doi.org/10.1111/j.1572-0241.2006.00734.x
122. Weizman Z, Asli G, Alsheikh A. Effect of a probiotic infant formula on infections in child care centers: comparison of two probiotic agents. Pediatrics 2005; 115:5-9; PMID:15629974
123. Cleusix V, Lacroix C, Vollenweider S, Le Blay G, Glycerol induces reuterin production and decreases Escherichia coli population in an in vitro model of colonic fermentation with immo bilized human feces. FEMS Microbiol Ecol 2008; 63:56-64; PMID:18028400; http://dx.doi.org/10.1111/j.1574-6941.2007.00412.x
124. Jones ML, Martoni CJ, Prakash S. Cholesterol lowering and inhibition of sterol absorption by Lactobacillus reuteri NCIMB 30242: a randomized controlled trial. Eur J Clin Nutr 2012; 66:1234-41; PMID:22990854; http://dx.doi.org/10.1038/ejcn.2012.126
125. Jones ML, Martoni CJ, Parent M, Prakash S. Cholesterol-lowering efficacy of a microencapsu-lated bile salt hydrolase-active Lactobacillus reuteri NCIMB 30242 yoghurt formulation in hypercho-lesterolaemic adults. Br J Nutr 2012; 107:1505-13; PMID:22067612; http://dx.doi.org/10.1017/S0007114511004703
126. Jones ML, Martoni CJ, Ganopolsky JG, Sulemankhil I, Ghali P, Prakash S. Improvement of gastrointestinal health status in subjects consuming Lactobacillus reuteri NCIMB 30242 capsules: a post-hoc analysis of a randomized controlled trial. Expert Opin Biol Ther 2013; 13:1643-51; PMID:24074303; http://dx.doi.org/10.1517/14712598.2013.833601
127. Jones ML, Martoni CJ, Prakash S. Letter to the editor regarding the report of Duboc et al. Connecting dys-biosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel disease. Gut 2013; 62:654-5; PMID:23148122; http://dx.doi.org/10.1136/gutjnl-2012-303867
128. Jones ML, Martoni CJ, Prakash S. Oral supplementation with probiotic L. reuteri NCIMB 30242 increases mean circulating 25-hydroxyvitamin D: a post hoc analysis of a randomized controlled trial. J Clin Endocrinol Metab 2013; 98:2944-51; PMID:23609838; http://dx.doi.org/10.1210/jc.2012-4262
129. Szajewska H, Ruszczyński M, Radzikowski A. Probiotics in the prevention of antibiotic-associated diarrhea in children: a meta-analysis of randomized controlled trials. J Pediatr 2006; 149:367-72; PMID:16939749; http://dx.doi.org/10.1016/j.jpeds.2006.04.053
130. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 2006; 101:812-22; PMID:16635227; http://dx.doi.org/10.1111/j.1572-0241.2006.00465.x
131. Szymański H, Pejcz J, Jawień M, Chmielarczyk A, Strus M, Heczko PB. Treatment of acute infectious diarrhoea in infants and children with a mixture of three Lactobacillus rhamnosus strains--a randomized, double-blind, placebo-controlled trial. Aliment Pharmacol Ther 2006; 23:247-53; PMID:16393304; http://dx.doi.org/10.1111/j.1365-2036.2006.02740.x
132. Hickson M, D’Souza AL, Muthu N, Rogers TR, Want S, Rajkumar C, Bulpitt CJ. Use of probi-otic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ 2007; 335:80; PMID:17604300; http://dx.doi.org/10.1136/bmj.39231.599815.55
133. Guandalini S. Probiotics for prevention and treatment of diarrhea. J Clin Gastroenterol 2011; 45(Suppl):S149-53; PMID:21992955; http://dx.doi.org/10.1097/MCG.0b013e3182257e98
134. Allen SJ, Martinez EG, Gregorio GV, Dans LF. Probiotics for treating acute infectious diarrhoea. Cochrane Database Syst Rev 2010; CD003048; PMID:21069673
135. Swidsinski A, Loening-Baucke V, Verstraelen H, Osowska S, Doerffel Y. Biostructure of fecal microbi-ota in healthy subjects and patients with chronic idio-pathic diarrhea. Gastroenterology 2008; 135:568-79; PMID:18570896; http://dx.doi.org/10.1053/j.gastro.2008.04.017
136. Kruis W, Fric P, Pokrotnieks J, Lukás M, Fixa B, Kascák M, Kamm MA, Weismueller J, Beglinger C, Stolte M, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004; 53:1617-23; PMID: 15479682; http://dx.doi.org/10.1136/gut.2003.037747
137. Tursi A, Brandimarte G, Papa A, Giglio A, Elisei W, Giorgetti GM, Forti G, Morini S, Hassan C, Pistoia MA, et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunc-tive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2010; 105:2218-27; PMID:20517305; http://dx.doi.org/10.1038/ajg.2010.218
138. Sood A, Midha V, Makharia GK, Ahuja V, Singal D, Goswami P, Tandon RK. The probiotic prepa ration, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2009; 7:1202-9, e1; PMID:19 63129 2; http://dx.doi.org/10.1016/j. cgh.2009.07.016
139. Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers KM, Brigidi P, Vitali B, Poggioli G, Miglioli M, Campieri M. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003; 124:1202-9; PMID:12730861; http://dx.doi.org/10.1016/S0016-5085(03)00171-9
140. Arthur JC, Gharaibeh RZ, Uronis JM, Perez-Chanona E, Sha W, Tomkovich S, Mühlbauer M, Fodor AA, Jobin C. VSL#3 probiotic modifies muco-sal microbial composition but does not reduce colitis-associated colorectal cancer. Sci Rep 2013; 3:2868; PMID:24100376; http://dx.doi.org/10.1038/srep02868